LON:SLN - Silence Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 45.35 -2.10 (-4.43 %) (As of 03/22/2019 01:02 PM ET)Previous CloseGBX 47.45Today's RangeGBX 44.78 - GBX 46.7352-Week RangeGBX 45.99 - GBX 191Volume53,280 shsAverage Volume13,380 shsMarket Capitalization£32.23 millionP/E Ratio-1.73Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. Receive SLN News and Ratings via Email Sign-up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SLN Previous Symbol CUSIPN/A CIKN/A Webwww.silence-therapeutics.com Phone+44-20-34576900Debt Debt-to-Equity RatioN/A Current Ratio7.70 Quick Ratio7.47Price-To-Earnings Trailing P/E Ratio-1.73 Forward P/E Ratio-2.55 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 35.94 per share Price / Cash Flow1.26 Book ValueGBX 49.70 per share Price / Book0.91Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares71,069,904Market Cap£32.23 million Next Earnings DateN/A OptionableNot Optionable Silence Therapeutics (LON:SLN) Frequently Asked Questions What is Silence Therapeutics' stock symbol? Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN." How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (LON:SLN) posted its earnings results on Tuesday, September, 11th. The company reported ($12.40) earnings per share for the quarter. View Silence Therapeutics' Earnings History. What price target have analysts set for SLN? 0 brokers have issued 12 month target prices for Silence Therapeutics' shares. Their forecasts range from GBX 277 to GBX 277. On average, they expect Silence Therapeutics' share price to reach GBX 277 in the next twelve months. This suggests a possible upside of 510.8% from the stock's current price. View Analyst Price Targets for Silence Therapeutics. Has Silence Therapeutics been receiving favorable news coverage? Headlines about SLN stock have been trending negative this week, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Silence Therapeutics earned a daily sentiment score of -2.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of Silence Therapeutics' key competitors? Some companies that are related to Silence Therapeutics include Matinas Biopharma (MTNB), Verseon (VSN), Circassia Pharmaceuticals (CIR), Equillium (EQ), Cynata Therapeutics (CYP), Mereo BioPharma Group (MPH), Immutep (IMM), Neuren Pharmaceuticals (NEU), Covalon Technologies (COV), Acasti Pharma (ACST), Medicure (MPH), Promis Neurosciences (PMN), Bionomics (BNO), 4d Pharma (DDDD) and CEL-SCI (CVM). What other stocks do shareholders of Silence Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), INTL CONS AIRL/S (ICAGY), PPHE Hotel Group (PPH), MJ Gleeson (GLE), Apergy (APY), Cairn Energy (CNE), Petrofac (PFC), OneSavings Bank (OSB) and Greggs (GRG). Who are Silence Therapeutics' key executives? Silence Therapeutics' management team includes the folowing people: Dr. David Horn Solomon, CEO & Director (Age 59)Dr. Rob Quinn, Interim CFO & Company Sec.Dr. Mark Cameron, Head of ChemistryMr. Richard Jenkins, Head of Clinical Devel. How do I buy shares of Silence Therapeutics? Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Silence Therapeutics' stock price today? One share of SLN stock can currently be purchased for approximately GBX 45.35. How big of a company is Silence Therapeutics? Silence Therapeutics has a market capitalization of £32.23 million. What is Silence Therapeutics' official website? The official website for Silence Therapeutics is http://www.silence-therapeutics.com/. How can I contact Silence Therapeutics? Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900. MarketBeat Community Rating for Silence Therapeutics (LON SLN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 157 (Vote Outperform)Underperform Votes: 144 (Vote Underperform)Total Votes: 301MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe SLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: How does a 12b-1 fee affect fund performance?